Inhaled nitric oxide therapy in neonatal hypoxic respiratory failure: Insights beyond primary outcomes

Seminars in Perinatology

Volumn 27, Issue 4, 2003, Pages 311-319

  Sokol, Gregory M ^a   Ehrenkranz, Richard A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALI; INOTROPIC AGENT; NITRIC OXIDE; SEDATIVE AGENT; SURFACTANT; VASODILATOR AGENT;

CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SCREENING; EXTRACORPOREAL OXYGENATION; HEALTH CARE ORGANIZATION; HIGH FREQUENCY VENTILATION; HUMAN; MEDICAL LITERATURE; MULTICENTER STUDY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NEWBORN CARE; NEWBORN HYPOXIA; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0042919560     PISSN: 01460005     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0146-0005(03)00043-0     Document Type: Article

References (40)

1. Gersony WM, Duc CV, Sinclair JD: "PFC" syndrome (persistence of fetal circulation). Circulation 40:111, 1969
2. Gersony WM: Neonatal pulmonary hypertension: Pathophysiology, classification, and etiology. Clin Perinatol 11:517-524, 1984
3. Graves ED 3rd, Redmond CR, Arensman RM: Persistent pulmonary hypertension in the neonate. Chest 93:638-641, 1988
4. Furchgott RF: Studies on relaxation of rabbit aorta by sodium nitrate: Basis for the proposal that the acid-activatable component of the inhibitory factor from retractor penis is inorganic nitrate and the endothelium-derived relaxing factor is nitric oxide, in Vanhoutte PM (ed): Mechanisms of Vasodilatation. New York, Raven, 1988, pp 401-414
5. Ignarro LJ, Buga GM, Wood KS, et al: Endothelium-derived relaxing factor (EDRF) produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84:9265-9269, 1987
6. Palmer RMJ, Ferrigo AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526, 1987
7. Roberts JD, Polaner DM, Lang P, et al: Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340:818-819, 1992
8. Kinsella JP, Neish SR, Shaffer E, et al: Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340:819-820, 1992
9. Tyson JE: Use of unproven therapies in clinical practice and research: How can we better serve our patients and their families? Semin Perinatol 19:98-111, 1995
10. Walsh-Sukys MC, Cornell DJ, Houston LN, et al: Treatment of persistent pulmonary hypertension of the newborn without hyperventilation: An assessment of diffusion of innovation. Pediatrics 94:303-306, 1994
11. Walsh-Sukys MC, Tyson JE, Wright LL, et al: Persistent pulmonary hypertension of the newborn in the era before nitric oxide: Practice variation and outcomes. Pediatrics 105:14-20, 2000
12. Centers for Disease Control: Recommendations for occupational safety and health standards. Morbid Mortal Wkly Rep 37:21 1988 (Suppl S7)
13. Frampton MW, Morrow PE, Cox C, et al: Effects of nitrogen dioxide exposure on pulmonary function and airway reactivity in normal humans. Am Rev Respir Dis 143:522-527, 1991
14. Etches PC, Harris ML, McKinley R, et al: Clinical monitoring of inhaled nitric oxide: comparison of chemiluminescent and electrochemical sensors. Biomed Instrum Technol 29:134-140, 1995
15. Goldman AP, Macrae DJ: Nitrogen dioxide measurement in breathing systems. Lancet 343:850, 1994 (letter)
16. Foubert L, Fleming B, Latimer R, et al: Safety guidelines for use of nitric oxide. Lancet 339:1615-1616, 1992 (letter)
17. Bouchet M, Renaudin MH, Raveau C, et al: Safety requirement for use of inhaled nitric oxide in neonates. Lancet 341:968-969, 1993 (letter)
18. Miyamoto K, Aida A, Nishimura M, et al: Effects of humidity and temperature on nitrogen dioxide formation from nitric oxide. Lancet 343:1099-1100, 1994 (letter)
19. Laguenie G, Berg A, Saint-Maurice JP, et al: Measurement of nitrogen dioxide formation from nitric oxide by chemiluminescence in ventilated children. Lancet 341: 969, 1993 (letter)
20. Nishimura M, Hess D, Kacmarek RM, et al: Nitrogen dioxide production during mechanical ventilation with nitric oxide in adults. Anesthesiology 82:1246-1254, 1995
21. Sokol GM, Van Meurs KP, Wright LL, et al: Nitrogen dioxide formation during inhaled nitric oxide therapy. Clin Chem 45:382-387, 1999
22. Van Meurs KP, Sokol GM, Wright LL, et al: Minimizing nitrogen dioxide exposure during inhaled nitric oxide therapy. Pediatr Res 39:353A, 1996 (abstr)
23. Zapol WM, Rimar S, Gillis N, et al: Nitric oxide and the lung. Am J Respir Crit Care Med 149:1375-1380, 1994
24. The Neonatal Inhaled Nitric Oxide Study Group: Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 336:597-604, 1997
25. Rossaint R, Falke KJ, Lopez F, et al: Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 328:399-405, 1993
26. Clark RH, Kueser TJ, Walker MW, et al: Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med 342:469-474, 2000
27. The Neonatal Inhaled Nitric Oxide Study Group (NINOS): Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics 99:838-845, 1997
28. The Neonatal Inhaled Nitric Oxide Study Group: Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS). J Pediatr 136:611-617, 2000
29. Bayley N: Bayley Scores of Infant Development, (ed 2) San Antonio, TX, The Psychological Corporation, 1993
30. Sokol GM, Fineberg NS, Wright LL, et al: Changes in arterial oxygen tension when weaning neonates from inhaled nitric oxide. Pediatr Pulmonol 32:14-19, 2001
31. Konduri GG, Solimano A, Sokol GM, et al: A randomized trial of early versus standard inhaled nitric oxide in term and near term newborn infants with hypoxic respiratory failure. Pediatrics (in press)
32. Jobe AH: Surfactant in the perinatal period. Early Hum Dev 29:57-62, 1992
33. Evans NJ, Archer LNJ: Doppler assessment of pulmonary artery pressure and extrapulmonary shunting in the acute phase of hyaline membrane disease. Arch Dis Child 66:6-11, 1991
34. Skinner JR, Boys RJ, Hunter S, et al: Pulmonary and systemic arterial pressure in hyaline membrane disease. Arch Dis Child 67:366-373, 1992
35. Walther FJ, Benders MJ, Leighton JO: Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics 90:899-904, 1992
36. Abman SH, Kinsella JP, Schaffer MS, et al: Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. Pediatrics 92:606-609, 1993
37. Peliowski A, Finer NN, Etches PC, et al: Inhaled nitric oxide for premature infants after prolonged rupture of the membranes. J Pediatr 126:450-453, 1995
38. Van Meurs KP, Rhine WD, Asselin JM, et al: Response of premature infants with severe respiratory failure to inhaled nitric oxide. Pediatr Pulmonol 24:319-323, 1997
39. Kinsella JP, Walsh WF, Bose CL, et al: Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: A randomized controlled trial. Lancet 354:1061-1065, 1999
40. The Franco-Belgium Collaborative Trial Group: Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: A randomized controlled trial. Lancet 354:1066-1071, 1999